Corticosteroids for bacterial keratitis: Who gets them?

JAMA Ophthalmology

Volumn 131, Issue 2, 2013, Pages 233-235

  Jones, Dan B ^a  

^a CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CORTICOSTEROID; MOXIFLOXACIN; PCRV PROTEIN; PSEUDOMONAS EXOTOXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRANSFERASE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; BACTERIAL KERATITIS; BACTERIAL STRAIN; CORNEA ULCER; CORTICOSTEROID THERAPY; EDITORIAL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; VISUAL ACUITY;

CORNEAL ULCER; EYE INFECTIONS, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84874048339     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.1610     Document Type: Editorial

References (19)

1. Shah A, Sachdev A, Coggon D, Hossain P. Geographic variations in microbial keratitis: an analysis of the peer-reviewed literature. Br J Ophthalmol. 2011; 95(6):762-767.
2. Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis: an evidence-based update. Ophthalmology. 2002;109(5):835-842; quiz 843.
3. Srinivasan M, Mascarenhas J, Rajaraman R, et al; Steroids for Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 2012;130(2):143-150.
4. Sy A, Srinivasan M, Mascarenhas J, et al. Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment. Invest Ophthalmol Vis Sci. 2012;53(1):267-272.
5. Borkar DS, Fleiszig SMJ, Leong C, et al. Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis. JAMA Ophthalmol. 2013;131(2):147-153.
6. Winstanley C, Kaye SB, Neal TJ, Chilton HJ, Miksch S, Hart CA; Microbiology Ophthalmic Group. Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis. J Med Microbiol. 2005; 54(pt 6):519-526.
7. Ajayi T, Allmond LR, Sawa T, Wiener-Kronish JP. Single-nucleotide- polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol. 2003;41(8):3526-3531.
8. Li L, Ledizet M, Kar K, Koski RA, Kazmierczak BI. An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of type III virulence phenotypes of Pseudomonas aeruginosa isolates. Ann Clin Microbiol Antimicrob. 2005;4(22):22.
9. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol. 2009;7(9):654-665.
10. Angus AA, Lee AA, Augustin DK, Lee EJ, Evans DJ, Fleiszig SMJ. Pseudomonas aeruginosa induces membrane blebs in epithelial cells, which are utilized as a niche for intracellular replication and motility. Infect Immun. 2008;76(5):1992-2001.
11. Sun Y, Karmakar M, Taylor PR, Rietsch A, Pearlman E. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J Immunol. 2012;188(4): 1884-1895.
12. Sawa T, Yahr TL, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med. 1999;5(4):392-398.
13. Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun. 2001;69(9):5908-5910.
14. Baer M, Sawa T, Flynn P, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun. 2009;77(3):1083-1090.
15. Arnoldo A, Curak J, Kittanakom S, et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen [published correction appears in PLoS Genet. 2008;4(4):doi: 10.1371/annotation/76d35829-07a2-479f-bbc1-cce6755b6d8c]. PLoS Genet. 2008;4(2):e1000005.
16. 2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun. 2007;75(3):1089-1098.
17. Janjua HA, Segata N, Bernabò P, Tamburini S, Ellen A, Jousson O. Clinical populations of Pseudomonas aeruginosa isolated from acute infections show a wide virulence range partially correlated with population structure and virulence gene expression. Microbiology. 2012;158(pt 8):2089-2098.
18. Hurley MN, Cámara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J. 2012;40(4): 1014-1023.
19. Williams P, Cámara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol. 2009;12(2):182-191.